Publications by authors named "K Oashi"
To summarize the current therapies for skin cancers, the Japanese Skin Cancer Society issued the first guidelines for skin cancers, including melanoma, squamous cell carcinoma, basal cell carcinoma (BCC), and extramammary Paget's disease, in 2007. These guidelines were revised in 2015. Herein, we present the English version of the 2021 edition of the Japanese clinical guidelines for BCC.
View Article and Find Full Text PDFArticle Synopsis
- Anti-PD-1 immunotherapy is less effective for Asian patients with advanced BRAF V600-mutant melanoma, leading researchers to consider alternative first-line treatments.
- A study analyzed treatment outcomes for 336 Asian patients using BRAF/MEK inhibitors, anti-PD-1, and PD-1/CTLA-4 combinations, revealing BRAF/MEKi had the best objective response rates and progression-free survival.
- The results suggested that BRAF/MEKi may be preferred over anti-PD-1 treatments for these patients, particularly in second-line settings, highlighting the need for tailored treatment approaches based on patient demographics.
Basal cell carcinoma is the most common type of skin cancer, and surgical excision with clear margins is the standard of care. Surgical margins are determined based on risk factors (high or low risk) for recurrence according to the National Comprehensive Cancer Network and Japanese basal cell carcinoma guidelines. The clarity of the clinical tumor border (well-defined or poorly defined) is considered a risk factor, and significant discrepancies in the judgment of clinical tumor borders among dermato-oncologists may occur.
View Article and Find Full Text PDFBackground: Paclitaxel is a standard of care for patients with primary cutaneous angiosarcoma of the scalp and face. However, no standard second-line treatment for paclitaxel-resistant patients has ever been established. Since primary cutaneous angiosarcoma expresses a high level of vascular endothelial growth factor receptor, the multitargeted tyrosine kinase inhibitor pazopanib seemed to be the most promising agent, and several retrospective studies have demonstrated its activity against this disease.
View Article and Find Full Text PDFBackground: In patients with cutaneous angiosarcoma of the scalp and face, the validity of surgery remains controversial, because of the potentially diffuse nature of involvement and difficulty in obtaining negative margins.
Objective: To evaluate the survival benefit of surgery as a primary treatment.
Patients And Methods: Fifty-one patients with primary cutaneous angiosarcoma of the scalp and face presenting with locoregional involvement were referred to National Cancer Center Hospital, Tokyo, Japan, between May 1982 and March 2013.